INVESTOR RELATIONS
Arterez is developing a platform of novel companion and predictive diagnostics, (GlocoCardia™, Glycalyx Detritus Fingerprint™) as well as multi-compound therapies, beginning with Embotricin™, a first of kind anti-embolic™ drug targeting the multi-factorial root causes of CVD, including the repair and maintenance of the endothelial glycocalyx, reducing inflammation and minimizing the damaging effects of oxidation.
Our platform may be a profound scientific breakthrough potentially revolutionizing the current standard/s of care for CVD and related vascular pathophysiologies.
Executive Summary
Arterez Inc. wholly owns GlycoTrx, LLC (diagnostic panels) and ComboRx, LLC (anti-embolic™ oral therapies)
Clinical target: In-human, proof of concept (PoC) studies for Embotricin™ and GlycoCardia™ against coronary heart disease, heart failure and hypertension (Timeline - Q2, 2023).
Arterez is also developing the Glycalyx Detritus Fingerprint™ technology, a novel diagnostic platform of therapeutic aides and diagnostic panels for vascular disease.
Embotricin™ is proven to prevent and reverse arterial plaques in pre-clinical animal studies with no toxicity up to 15x the effective dose in observational animal studies.
Patent portfolio includes;
Methods and compositions for reversing disruption of the glycocalyx, inflammation and oxidative damage
Biomarkers of vascular disease
Drug treatment and biomarker panel targeted to diseases due to multi-factorial ontology of glycocalyx disruption
Animal model for CVD and inflammation. (Link available after filing)
Notes:
International PCT:
Submissions to begin in Q3, 2020
Trademarks:
Arterez, GlycoCardia, Embotricin
Trademarks in Application:
'Tunac Arterial Plaque' (TAP) animal model, 'Anti-Embolics', 'Glycalyx Detritus Fingerprint' (GDF), 'Zeno-Pathology'
Grant Applications:
SBIR and Omnibus grant applications in process. Actively seeking university & business collaborations
Freedom to Operate (FTO) search:
Findings available June, 2020
Business plan:
Next update available June, 2020
Series A:
Available Q3, 2020.
2012-2017
2018-2023
Dr. Josephino Tunac launched
Farmaceutix, LLC (FTX)
R&D for anti-embolic bio-
markers and compounds*
Rationally synthesized 9
synthetic compounds
3x combo proved to prevent
& reverse arterial plaques
New studies launched with
natural mouse, biomarkers
Compounds/methods,
biomarker patents filed
Surrogate markers identified for
development/testing of compounds
Developed natural arterial
plaque mouse model
Combo drug proved non-toxic
up to 20x the effective dose
Engaged firm to assist with platform
development and funding
FTX continues testing & development
of additional intellectual properties
Patent filings amended, audit completed, development pathway established
Arterez launched, FTX IP
assigned, team developed
Website built, new IP filed &
issued, providers engaged
IRB studies, compounds to GLP, SBIR/Omnimus grants
ELISA & animal studies, GAP
analysis, plan updated, series A
Phase I healthy, limited 1B
studies vs CHD, HF & HTN
IP valuation, engage licensing
partner/s and/or suitors
Seed raise, biomarkers added,
ELISA & HFHS** studies engaged
Website built, new IP filed &
issued, providers engaged
Formulation, optimization, stability,
chronic toxicology, pre-IND
Series B, patient recruitment,
Australia submissions, IND/IRB filings
Complete co-dev, licensing or other
for diagnostic and therapy
Consider IPO to continue
platform development
Development Timeline
Scientific Breakthrough
Historical development of antibiotic targeting microorganisms leading to cure of infectious disease. An equivalent approach is to target endothelial glycocalyx to cure CVD by an antiembolic™ mechanism.
